The study is seeking to create a repository of blood samples from participants who have a history of testing positive for COVID-19 to help accelerate current and future COVID-19 research.
This patient registry aims to recruit people who have recovered following infection with SARS-CoV-2 / COVID-19 for the purpose of connecting them with researchers in the United States who are conducting research to learn about the survivor experience, and develop new treatments for patients currently with the illness.
While much has been learned about the acute phase of Coronavirus disease 2019 (COVID-19) in the last year, little is known about the recovery phase. There have recently been several reports in the news and in the medical literature about a prolonged recovery phase after developing acute COVID-19 in some individuals who may have persistent symptoms many months after infection, developing the so called “long COVID”.
The primary aim of this study is to obtain observational physiological signals from patients previously discharged from hospitalization at Tufts Medical Center between 2019 to present (est enrollment starting in June 2022) with positive diagnosis of COVID-19 to further our understanding and characterization of Long COVID-19 syndrome using combined medical histories and continuous physiological signals captured through wearable devices such as the Oura Ring, Fitbit, AliveCor KardiaMobile, and Samsung Watch3 type devices.
This is a research study being conducted in patients who tested positive for COVID-19 in the past 10 days and are admitted to the hospital. The study is being conducted to assess the safety of an experimental drug called Reparixin. This is provided as tablets along with standard treatment to limit progression of Covid-19 disease. This is a randomized, (which means just like tossing a coin, you will be randomly assigned to receive the study drug or the standard treatment) double-blind trial (which means neither you nor the study team will know which group you are assigned to).
This study is being conducted in healthy children from age 6 months to age 12 years. The study is looking at how well the Moderna mRNA vaccine works when given to healthy children for the prevention of COVID-19.
This is a prospective, multi-center, multi-arm, double-blind, randomized, controlled platform trial evaluating antiviral and other therapeutics for use in the treatment of Post-Acute Sequelae of COVID-19 (PASC). The hypothesis is that persistent viral infection and/or overactive/chronic immune response are underlying contributors to PASC and that antiviral and other applicable therapies may result in viral clearance or decreased inflammation and improvement in PASC symptoms.
The purpose of the study is to learn about the problems that some individuals who recover from a COVID-19 infection continue to have months after they recover from the initial phase of the infection. We will be performing specific type of imaging called x-ray velocimetry. This allows us to understand regional lung ventilation. We will be examining if the measures of regional lung ventilation are more abnormal in participants who have previously had COVID-19 compared to those who have not previously acquired this infection.
The primary objective of this study is to assess the efficacy of rifaximin SSD-40IR versus placebo to delay the occurrence of HE-related hospitalization.
The purpose of this study is to characterize cardiac safety of Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCd) treatment regimens (Arm A: immediate daratumumab + VCd treatment and Arm B: daratumumab + deferred VCd) in newly diagnosed systemic amyloid light chain (AL) amyloidosis with cardiac involvement and to identify potential mitigation strategies for cardiac toxicity (cohort 1); to characterize the pharmacokinetics of subcutaneous (SC) daratumumab, among racial and ethnic minorities, including Black or African American, with newly diagnosed AL amyloidosis treated wi
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival.
